


Ralimetinib

Cat. No.:	HY-13241A
CAS No.:	862505-00-8
Molecular Formula:	C ₂₄ H ₂₉ FN ₆
Molecular Weight:	420.53
Target:	p38 MAPK; Autophagy
Pathway:	MAPK/ERK Pathway; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β , with IC ₅₀ s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38 α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc ^[1] .	
IC₅₀ & Target	p38 β MAPK 3.2 nM (IC ₅₀)	p38 α MAPK 5.3 nM (IC ₅₀)

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Nat Commun. 2021 Dec 3;12(1):6941.
- Cell Death Dis. 2021 Oct 23;12(11):994.
- Glia. 2020 Jan;68(1):27-43.
- EBioMedicine. 2015 Nov 19;2(12):1944-56.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA